Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: A multi-centre study on clinical outcome and therapeutic options

Clinical Microbiology and Infection

Volumn 20, Issue 2, 2014, Pages

  Kontopidou, F ^a   Giamarellou, H ^b   Katerelos, P ^a   Maragos, A ^a   Kioumis, I ^c   Trikka Graphakos, E ^d   Valakis, C ^e   Maltezou, H C ^a   Eleni, Aimoniotou ^f   Susana, Anisoglou ^g   Eleni, Antonoglou ^o   Chrisi, Bella Tsanaka ^l   Emmanouil, Bolikas ^m   Vasiliki, Chatzipantazi ⁱ   Chouris, Isaac ^r   Georgios, Daikos ^s   Ioannis, Daskalakis ^o   Eleni, Fakiri ^e   Eleni, Kaitsa Tsiopoulou ^g   Maria, Katsiari ^k   Vasiliki, Liakou ^r   Eleftheria, Lionaki ^k   Fani, Markou ⁱ   Konstantina, Moldovanidou ^f   Eva Otilia, Nagky ^l   Evangelia, Platsouka ^b   Zoi, Roussou ^b   Ilias, Samiotis ^t   Apostolos, Sgouradis ^h   Lydia, Sianidou ^q   Giannoula, Stamatopoulou ^j   Ioanna, Stefanou ^s   Vassiliki, Theodorou ^p   Eleni, Tsorlini ⁿ   Aristidis, Vakalos ^j   Heleni, Hatzivasileiou ^h   more..

^a Hellenic Center for Disease Control and Prevention   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d THRIASIO GENERAL HOSPITAL   (Greece)

^e SISMANOGLIO HOSPITAL   (Greece)

^f Aristotle University of Thessaloniki   (Greece)

^g Cancer Hospital Theagenio   (Greece)

^h Prefectural General Hospital of Drama   (Greece)

ⁱ General District Hospital of Serres   (Greece)

^j Xanthi General Hospital   (Greece)

^k Chania General Hospital St George   (Greece)

^l Kavala General Hospital   (Greece)

^m General Hospital of Heraclio Venizeleio   (Greece)

ⁿ G PAPANICOLAOU HOSPITAL   (Greece)

^o Rhodes General Hospital   (Greece)

^p DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^q PENTELI CHILDREN S HOSPITAL   (Greece)

^r Giannitsa General Hospital   (Greece)

^s LAIKO GENERAL HOSPITAL   (Greece)

^t General Hospital of Rethymno   (Greece)

more..

Author keywords

Carbapenem resistance; Intensive care unit; Klebsiella pneumoniae; KPC; Mortality

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CARBAPENEM; COLISTIN; GENTAMICIN; MEROPENEM; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; CENTRAL VENOUS CATHETER; FEMALE; GREECE; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LOADING DRUG DOSE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME; TREATMENT RESPONSE; VENTILATOR ASSOCIATED PNEUMONIA;

KLEBSIELLA PNEUMONIAE;

CARBAPENEM-RESISTANCE; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; KPC; MORTALITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CARBAPENEMS; FEMALE; GREECE; HUMANS; INTENSIVE CARE UNITS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892479911     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12341     Document Type: Article

References (39)

1. Daikos GL, Petrikkos P, Psichogiou M et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 2009; 53: 1868-1873.
2. Maltezou HC, Giakkoupi P, Maragos A et al. Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete Greece. J Infect 2009; 58: 213-219.
3. Souli M, Galani I, Antoniadou A et al. An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek university hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis 2010; 50: 364-373.
4. Maltezou HC. Metallo-β-lactamases in Gram-negative bacteria: introducing the eraof pan-resistance? Int J Antimicrob Agents 2009; 33: 405.e1-7.
5. Souli M, Kontopidou FV, Papadomichelakis E, Galani I, Armaganidis A, Giamarellou H. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek university hospital. Clin Infect Dis 2008; 46: 847-854.
6. Grundmann H, Livermore DM, Giske CG et al. Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill 2010; 15: pii:19711.
7. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010; 65: 1119-1125.
8. Bergen PJ, Landersdorfer CB, Zhang J et al. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new? Diagn Microbiol Infect Dis 2012; 74: 213-223.
9. Michalopoulos AS, Karatza DC, Gregorakos L. Pharmacokinetic evaluation of colistin sodium. Expert Opin Drug Metab Toxicol 2011; 7: 245-255.
10. Giamarellou H, Poulakou G. Pharmacokinetic and pharmacodynamic evaluation of tigecycline. Expert Opin Drug Metab Toxicol 2011; 7: 1459-1470.
11. Kontopidou F, Plachouras D, Papadomichelakis E et al. Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients. Clin Microbiol Infect 2011; 17: E9-E11.
12. Antoniadou A, Kontopidou F, Poulakou G et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother 2007; 59: 786-790.
13. Matthaiou DK, Michalopoulos A, Rafailidis PI et al. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med 2008; 36: 807-811.
14. Vatopoulos A. High rates of metallo-β-lactamase-producing Klebsiella pneumoniae in Greece. A review of the current evidence. Euro Surveill 2008; 13 pii: 8023.
15. Giakoupi P, Maltezou H, Polemis M et al. KPC-2-producing Klebsiella pneumoniae infections in Greek hospitals are mainly due to a hyperepidemic clone. Euro Surveill 2009; 21: pii:19218.
16. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of healthcare-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36: 309-332.
17. Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 20th Informational Supplement M100-S20-U. Wayne, PA, USA: CLSI, 2010.
18. The European Committee on Antimicrobial Susceptibility Testing-EUCAST. Clinical Breakpoints. Available at: http://www.eucast.org/ (Accessed 23 October 2012).
19. Tsakris A, Kristo I, Poulou A et al. Evaluation of boronic acid disk tests for differentiating KPC-possessing Klebsiella pneumoniae isolates in the clinical laboratory. J Clin Microbiol 2009; 47: 362-367.
20. Tsakris A, Poulou A, Pournaras S et al. Α simple phenotypic method for the differentiation of metallo-β-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates. J Antimicrob Chemother 2010; 65: 1664-1671.
21. Zarkotou O, Pournaras S, Tselioti P et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011; 17: 1798-1803.
22. Mouloudi E, Protonotariou E, Zagorianou A et al. Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect Control Hosp Epidemiol 2010; 31: 1250-1256.
23. Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis 2012; 14: 198-205.
24. Qureshi ZA, Paterson DL, Peleg AY et al. Clinical characteristics of bacteraemia caused by extended -spectrum β-lactamase-producing Enterobacteriaceae in the era of CTX-M-type and KPC type β-lactamases. Clin Microbiol Infect 2012; 18: 887-893.
25. Tumbarello M, Viale P, Viscoli C et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55: 943-950.
26. Simsek F, Gedik H, Yildirmak MT et al. Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: monotherapy or combination therapy? Indian J Med Microbiol 2012; 30: 448-452.
27. Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 2008; 14: 816-827.
28. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012; 25: 682-707.
29. Poulakou G, Kontopidou FV, Paramythiotou E et al. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. J Infect 2009; 58: 273-284.
30. Neuner EA, Yeh JY, Hall GS et al. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis 2011; 69: 357-362.
31. Tigecycline package. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021821s021lbl.pdf (Accessed 23 October 2012).
32. Daly MW, Riddle DJ, Ledeboer NA, Dunne WM, Ritchie DJ. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae. Pharmacotherapy 2007; 27: 1052-1057.
33. Al-Qadheeb NS, Althawadi S, Alkhalaf A, Hosaini S, Alrajhi AA. Evolution of tigecycline resistance in Klebsiella pneumoniae in a single patient. Ann Saudi Med 2010; 30: 404-407.
34. Spanu T, De Angelis G, Cipriani M et al. In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumonia and Escherichia coli. Antimicrob Agents Chemother 2012; 56: 4516-4518.
35. Rodríguez-Avial C, Rodríguez-Avial I, Merino P, Picazo JJ. Klebsiella pneumoniae: development of a mixed population of carbapenem and tigecyclineresistance during antimicrobial therapy in a kidney transplant patient. Clin Microbiol Infect 2012; 18: 61-66.
36. FDA. A drug safety communication:increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. 2010. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm (Accessed 23 October 2012).
37. Qureshi ZA, Paterson DL, Potoski BA et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regiments. Antimicrob Agents Chemother 2012; 56: 2108-2113.
38. Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect 2011; 17: 1135-1141.
39. Poulou A, Voulgari E, Vrioni G et al. Klebsiella pneumoniae carbapenemase-producing K. pneumoniae clones in a Greek hospital: impact of infection control measures for restraining their dissemination. J Clin Microbiol 2012; 50: 2618-2623.